These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30573532)

  • 1. Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma.
    Pabon C; Esnakula AK; Daily K
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30573532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Lysis Syndrome due to Eribulin Administration for Metastatic Undifferentiated Pleomorphic Sarcoma of the Buttock.
    Tsuchie H; Miyakoshi N; Nagasawa H; Shimada Y
    Acta Med Okayama; 2021 Aug; 75(4):533-538. PubMed ID: 34511623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.
    Aliberti S; Miano S; Tolomeo F; Merlini A; Aglietta M; Grignani G
    Future Oncol; 2020 Jan; 16(1s):15-19. PubMed ID: 31916842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
    Osgood CL; Chuk MK; Theoret MR; Huang L; He K; Her L; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Nov; 23(21):6384-6389. PubMed ID: 28242632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumour lysis syndrome in a chemotherapy naïve patient with metastatic pancreatic adenocarcinoma.
    Saleh RR; Rodrigues J; Lee TC
    BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25634858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of tumor lysis syndrome following chemotherapy for a uterine epithelioid leiomyosarcoma with focal rhabdomyosarcomatous differentiation.
    Hiraizumi Y; Kamoi S; Inde Y; Kurose K; Ohaki Y; Takeshita T
    J Obstet Gynaecol Res; 2011 Jul; 37(7):947-52. PubMed ID: 21410837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
    Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
    Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin in advanced liposarcoma and leiomyosarcoma.
    Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
    Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
    Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
    Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasburicase for Tumor Lysis Syndrome.
    Vishwanathan S; Arumugarajah A; Ortega LM; Bousamra A
    Am J Ther; 2019; 26(1):e118-e121. PubMed ID: 27563802
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.
    Gouveia HS; Lopes SO; Faria AL
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29545434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
    Ohtani S; Nakayama T; Yoshinami T; Watanabe KI; Hara F; Sagara Y; Kawaguchi H; Higaki K; Matsunami N; Hasegawa Y; Takahashi M; Mizutani M; Morimoto T; Sato M; Itoh M; Morita S; Masuda N
    Breast Cancer; 2018 Jul; 25(4):438-446. PubMed ID: 29435730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leiomyosarcoma of the uterus: a clinicopathological report of two cases and review of literature.
    Omoniyi-Esan GO; Badmos KB; Adeyemi AB; Rotimi O
    Afr J Med Med Sci; 2008 Sep; 37(3):285-8. PubMed ID: 18982823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine myxoid leiomyosarcoma.
    Kasahara K; Nishida M; Iijima S; Kaneko M
    Obstet Gynecol; 2000 Jun; 95(6 Pt 2):1004-6. PubMed ID: 10808004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.
    de Nonneville A; Sabatier R; Gonçalves A; Extra JM; Tarpin C; Launay S; Tassy L; Viens P; Rousseau F
    J Geriatr Oncol; 2018 May; 9(3):281-283. PubMed ID: 29174186
    [No Abstract]   [Full Text] [Related]  

  • 19. Massive myxoid leiomyosarcoma of the uterus.
    Vigone A; Giana M; Surico D; Leutner M; Surico N
    Int J Gynecol Cancer; 2005; 15(3):564-7. PubMed ID: 15882188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
    Kobayashi T; Tomomatsu J; Fukada I; Shibayama T; Teruya N; Ito Y; Iwase T; Ohno S; Takahashi S
    BMC Cancer; 2016 Jul; 16():404. PubMed ID: 27389013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.